Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$800M |
| 2 |
NVIDIA
NVDA
|
+$304M |
| 3 |
Broadcom
AVGO
|
+$261M |
| 4 |
Linde
LIN
|
+$237M |
| 5 |
JPMorgan Chase
JPM
|
+$208M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Costco
COST
|
+$656M |
| 2 |
Netflix
NFLX
|
+$632M |
| 3 |
Tesla
TSLA
|
+$474M |
| 4 |
Procter & Gamble
PG
|
+$428M |
| 5 |
Micron Technology
MU
|
+$332M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.04% |
| 2 | Healthcare | 15.34% |
| 3 | Industrials | 11.14% |
| 4 | Consumer Discretionary | 10.86% |
| 5 | Financials | 10.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2201
Journey Medical
DERM
$169M
| $1.14M | ﹤0.01% |
242,500
-1,500
| -0.6% | -$11.6K |
2023 Q2
11 quarters
|
|
2202
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$11.5B
| $1.14M | ﹤0.01% |
7,799
+234
| +3% | +$35.4K |
2025 Q1
4 quarters
|
|
2203
MetroCity Bankshares
MCBS
$1B
| $1.13M | ﹤0.01% |
+39,549
| New | +$1.12M |
2026 Q1
0 quarters
|
|
2204
FreightCar America
RAIL
$208M
| $1.13M | ﹤0.01% |
141,900
-1,800
| -1% | -$20.4K |
2023 Q4
9 quarters
|
|
2205
Broadstone Net Lease
BNL
$3.53B
| $1.13M | ﹤0.01% |
61,900
-192,800
| -76% | -$3.63M |
2025 Q4
1 quarter
|
|
2206
Grace Therapeutics
GRCE
$42.9M
| $1.13M | ﹤0.01% |
243,910
+114,129
| +88% | +$448K |
2024 Q3
6 quarters
|
|
2207
Mayville Engineering Co
MEC
$379M
| $1.13M | ﹤0.01% |
62,900
-8,300
| -12% | -$160K |
2024 Q2
7 quarters
|
|
2208
DLH Holdings
DLHC
$61M
| $1.13M | ﹤0.01% |
193,564
-16,500
| -8% | -$95.4K |
2013 Q2
51 quarters
|
|
2209
Franklin Street Properties
FSP
$39.1M
| $1.12M | ﹤0.01% |
1,692,603
+304,177
| +22% | +$235K |
2014 Q3
46 quarters
|
|
2210
OP Bancorp
OPBK
$225M
| $1.12M | ﹤0.01% |
84,400
-13,800
| -14% | -$190K |
2019 Q3
26 quarters
|
|
2211
ADC Therapeutics
ADCT
$236M
| $1.12M | ﹤0.01% |
+299,278
| New | +$1.18M |
2026 Q1
0 quarters
|
|
2212
Inovio Pharmaceuticals
INO
$113M
| $1.12M | ﹤0.01% |
643,777
+90,613
| +16% | +$149K |
2022 Q1
16 quarters
|
|
2213
Werner Enterprises
WERN
$1.97B
| $1.12M | ﹤0.01% |
+38,063
| New | +$1.23M |
2026 Q1
0 quarters
|
|
2214
Acumen Pharmaceuticals
ABOS
$147M
| $1.12M | ﹤0.01% |
473,946
+50,846
| +12% | +$130K |
2024 Q2
7 quarters
|
|
2215
U.S. Targeted Value Portfolio ETF Class Shares
DFAT
$13.9B
| $1.12M | ﹤0.01% |
+17,900
| New | +$1.14M |
2026 Q1
0 quarters
|
|
2216
The Beachbody Company
BODI
$34.6M
| $1.12M | ﹤0.01% |
102,864
+50,095
| +95% | +$499K |
2022 Q2
15 quarters
|
|
2217
Brazil Potash Corp
GRO
$136M
| $1.12M | ﹤0.01% |
344,700
+195,100
| +130% | +$552K |
2025 Q2
3 quarters
|
|
2218
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.45B
| $1.12M | ﹤0.01% |
+12,200
| New | +$1.14M |
2026 Q1
0 quarters
|
|
2219
Tandem Diabetes Care
TNDM
$1.14B
| $1.12M | ﹤0.01% |
+58,227
| New | +$1.27M |
2026 Q1
0 quarters
|
|
2220
Apyx Medical
APYX
$109M
| $1.12M | ﹤0.01% |
302,395
+82,000
| +37% | +$306K |
2015 Q1
44 quarters
|
|
2221
Sanara MedTech
SMTI
$323M
| $1.11M | ﹤0.01% |
64,680
+27,078
| +72% | +$557K |
2023 Q3
10 quarters
|
|
2222
Sylvamo
SLVM
$1.24B
| $1.11M | ﹤0.01% |
26,300
-37,400
| -59% | -$1.75M |
2021 Q4
17 quarters
|
|
2223
Westwater Resources
WWR
$55.2M
| $1.11M | ﹤0.01% |
1,692,190
-1,144,700
| -40% | -$1.03M |
2024 Q2
7 quarters
|
|
2224
Sight Sciences
SGHT
$491M
| $1.11M | ﹤0.01% |
293,358
+17,458
| +6% | +$94.2K |
2023 Q2
11 quarters
|
|
2225
Five Star Bancorp
FSBC
$1.06B
| $1.11M | ﹤0.01% |
29,300
-6,300
| -18% | -$242K |
2023 Q1
12 quarters
|
|
Similar funds
Renaissance Technologies's Q1 2026 Portfolio in Review
As of Q1 2026, Renaissance Technologies held 3,809 positions worth $63.9B, down 0.82% from $64.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2026 filing shows 624 new, 1,320 increased, 1,262 reduced and 596 closed positions. Its largest new stake was Apple: 3,075,638 shares worth $781M. The largest sale was Costco, an estimated $656M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Industrials.
- Renaissance Technologies's largest Q1 2026 buy was Apple: 3,075,638 shares worth $781M.
- Renaissance Technologies added most to NVIDIA in Q1 2026, an estimated $304M increase.
- Renaissance Technologies's biggest Q1 2026 reduction was Costco, cutting an estimated $656M.
- Renaissance Technologies fully exited Procter & Gamble in Q1 2026, selling an estimated $428M.
- Renaissance Technologies's ten largest holdings make up 11% of its $63.9B portfolio in Q1 2026.
- Renaissance Technologies opened 624 new positions and closed 596 in Q1 2026.
- Renaissance Technologies's portfolio value fell 0.82% quarter-over-quarter to $63.9B.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.